Whatman's CombiChip Wins CE Mark, Launches In Germany, and Is Being Evaluated for North America | GenomeWeb
Fresh from winning the CE Mark as an in vitro diagnostic, Whatman’s multiplex protein chip for autoimmune diseases is ready to launch in Germany, and the company is figuring out the steps it needs to take to begin selling it in the US, Whatman announced last week.
 
The chip, whose CE Mark came eight months later than had been originally expected, was co-developed with Privates Institut für Immunologie und Molekulargenetik, a German laboratory specializing in autoimmune and other clinical diagnostic assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.